VolitionRx Limited (VNRX) Analysts See $-0.16 EPS on May, 10

May 3, 2018 - By Sarah Harris

VolitionRx Limited (NYSEAMERICAN:VNRX) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.2. That’s change of 5.80, from 2017Q3’s 7. 3 investors sold all, 2 reduced holdings as VolitionRx Limited ratio fall. 4 increased stakes while 2 funds bought stakes. Funds hold 4.52 million shares thus 51.36% less from 2017Q3’s 9.30 million shares.
Brown Brothers Harriman & Co invested in 3,823 shs or 0% of the stock. Bankshares Of Ny Mellon reported 10,335 shs. Morgan Stanley has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Knoll Capital Mgmt Limited Partnership holds 0.91% or 351,538 shs in its capital. Bessemer Gp holds 0% or 10,000 shs. 22,714 are owned by Northern. 74,863 are owned by Leisure Cap. Blackrock stated it has 11,219 shs or 0% of all its holdings. Geode Capital Ltd holds 0% in VolitionRx Limited (NYSEAMERICAN:VNRX) or 100,890 shs. Bridgeway Management invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Creative Planning owns 13,200 shs. Royal Fincl Bank Of Canada holds 14,007 shs or 0% of its capital. Lagoda Mgmt Limited Partnership stated it has 3.94% in VolitionRx Limited (NYSEAMERICAN:VNRX). Vanguard owns 204,994 shs for 0% of their capital. Garrison Bradford & holds 0.04% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX) for 15,500 shs.

On May, 10 WallStreet awaited VolitionRx Limited (NYSEAMERICAN:VNRX)’s earnings release, as reported by RTT. Analysts predict $-0.16 earnings per share, which is $0.03 down or 23.08 % from 2017’s $-0.13 earnings per share. 6.67 % negative EPS growth is what analysts predict. $-0.15 earnings per share was revealed for last quarter. Ticker’s shares touched $2.0168 during the last trading session after 0.34% change.VolitionRx Limited has volume of 8,457 shares. Since May 3, 2017 VNRX has declined 42.82% and is downtrending. VNRX underperformed the S&P 500 by 54.37%.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers.The company has $60.54 million market cap. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.Currently it has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: